Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer
The study compared the levels of MMP-2,7,8,9, and TIMP-1 in blood serum of healthy people ( N =97) and patients with primary renal cell carcinoma ( N =93) to assess relevance of these markers to prognosis of overall survival of these patients, which were followed-up over 1 to 45 months (median 26 mo...
Gespeichert in:
| Veröffentlicht in: | Bulletin of experimental biology and medicine 2020-03, Vol.168 (5), p.673-676 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 676 |
|---|---|
| container_issue | 5 |
| container_start_page | 673 |
| container_title | Bulletin of experimental biology and medicine |
| container_volume | 168 |
| creator | Kushlinskii, N. E. Gershtein, E. S. Alferov, A. A. Bezhanova, S. D. Mushtenko, V. V. Pushkar, D. Yu Matveev, V. B. Stilidi, I. S. |
| description | The study compared the levels of MMP-2,7,8,9, and TIMP-1 in blood serum of healthy people (
N
=97) and patients with primary renal cell carcinoma (
N
=93) to assess relevance of these markers to prognosis of overall survival of these patients, which were followed-up over 1 to 45 months (median 26 months). To evaluate the survival with the
Kaplan—Meier
estimator, the median values of examined markers in the total group of patients were taken as the threshold levels. This estimator showed that the high levels of serum MMP-7 and MMP-8 were indicative for
unfavorable prognosis in the total group of patients with r
enal cell cancer. Of them, the most significant marker was the level of MMP-7: at its low level ( |
| doi_str_mv | 10.1007/s10517-020-04778-w |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2386432558</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A628510033</galeid><sourcerecordid>A628510033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-1c664409c4a67dd60cbfd78ac57b9168b16afc37b0a18958ecfb22ce36f764a13</originalsourceid><addsrcrecordid>eNp9kl1rFDEYhQdRbK3-AS8kIIgXOzVfk2Qu6-JHscWi63XIZN7ZTZlN1iTDur_Av23WrdqKSC5Ckucc3kNOVT0l-JRgLF8lghsia0xxjbmUqt7eq45JI1mtKCX3q2NcqJorpY6qRyld749YkIfVEaOUK87b4-r7VQxLH1J2Fn0KI6AwoEuTo_uGLiGbcQybGDI4bxIkRGdIzpCaoRYZ36PFClxEi90GEEELl9IE6NyvXOdyiMh59HoMoUefIU7rvfGVyQ58Tmjr8gp9cL2HHZobbyE-rh4MZkzw5GY_qb68fbOYv68vPr47n59d1JZLlmtiheAct5YbIfteYNsNvVTGNrJriVAdEWawTHbYENU2CuzQUWqBiUEKbgg7qV4efEusrxOkrNcuWRhH4yFMSVOmBGe0aVRBn_-FXocp-jJdoVoiWyzYLWppRtDODyFHY_em-kxQ1ZSfYqxQp_-gyuph7WzwMLhyf0fw4pZgBWbMqxTGKbvg012QHkAbQ0oRBr2Jbm3iThOs9zXRh5roUhP9syZ6W0TPbqJN3Rr635JfvSgAOwCpPPklxD_Z_2P7A02rxKs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2391790638</pqid></control><display><type>article</type><title>Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kushlinskii, N. E. ; Gershtein, E. S. ; Alferov, A. A. ; Bezhanova, S. D. ; Mushtenko, V. V. ; Pushkar, D. Yu ; Matveev, V. B. ; Stilidi, I. S.</creator><creatorcontrib>Kushlinskii, N. E. ; Gershtein, E. S. ; Alferov, A. A. ; Bezhanova, S. D. ; Mushtenko, V. V. ; Pushkar, D. Yu ; Matveev, V. B. ; Stilidi, I. S.</creatorcontrib><description>The study compared the levels of MMP-2,7,8,9, and TIMP-1 in blood serum of healthy people (
N
=97) and patients with primary renal cell carcinoma (
N
=93) to assess relevance of these markers to prognosis of overall survival of these patients, which were followed-up over 1 to 45 months (median 26 months). To evaluate the survival with the
Kaplan—Meier
estimator, the median values of examined markers in the total group of patients were taken as the threshold levels. This estimator showed that the high levels of serum MMP-7 and MMP-8 were indicative for
unfavorable prognosis in the total group of patients with r
enal cell cancer. Of them, the most significant marker was the level of MMP-7: at its low level (<6.3 ng/ml), a 3-year survival was 93%, whereas survival dropped down to 51% at a higher value of this marker (
p
<0.001). For MMP-8, the threshold level was 51 ng/ml, and the corresponding survivals were 78 and 58% (
p
<0.01). The level of MMP-7 was also prognostically significant for the patients with stage I kidney cancer: during a 3-year follow-up, all the patients with low MMP-7 were alive, while the 3-year survival of the patients with a high level of MMP-7 was only 72% (
p
=0.02). There were the declining trends for survival at high TIMP-1 and low MMP-2. In contrast, the level of MMP-9 virtually did not correlate with survival of the patients with renal cell cancer.</description><identifier>ISSN: 0007-4888</identifier><identifier>EISSN: 1573-8221</identifier><identifier>DOI: 10.1007/s10517-020-04778-w</identifier><identifier>PMID: 32248449</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - blood ; Biomedical and Life Sciences ; Biomedicine ; Blood cancer ; Cancer ; Cancer patients ; Carcinoma, Renal Cell - blood ; Carcinoma, Renal Cell - diagnosis ; Case-Control Studies ; Cell Biology ; Comparative analysis ; Female ; Gelatinase A ; Gelatinase B ; Humans ; Internal Medicine ; Kidney cancer ; Kidney Neoplasms - blood ; Kidney Neoplasms - diagnosis ; Kidneys ; Laboratory Medicine ; Male ; Matrilysin ; Matrix metalloproteinase ; Matrix Metalloproteinase 2 - blood ; Matrix Metalloproteinase 7 - blood ; Matrix Metalloproteinase 8 - blood ; Matrix Metalloproteinase 9 - blood ; Matrix Metalloproteinases - blood ; Medical prognosis ; Middle Aged ; Neutrophil collagenase ; Oncology ; Oncology, Experimental ; Pathology ; Predictive Value of Tests ; Prognosis ; Renal cell carcinoma ; Tissue inhibitor of metalloproteinase 1 ; Tissue Inhibitor of Metalloproteinase-1 - blood ; Young Adult</subject><ispartof>Bulletin of experimental biology and medicine, 2020-03, Vol.168 (5), p.673-676</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-1c664409c4a67dd60cbfd78ac57b9168b16afc37b0a18958ecfb22ce36f764a13</citedby><cites>FETCH-LOGICAL-c473t-1c664409c4a67dd60cbfd78ac57b9168b16afc37b0a18958ecfb22ce36f764a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10517-020-04778-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10517-020-04778-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32248449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kushlinskii, N. E.</creatorcontrib><creatorcontrib>Gershtein, E. S.</creatorcontrib><creatorcontrib>Alferov, A. A.</creatorcontrib><creatorcontrib>Bezhanova, S. D.</creatorcontrib><creatorcontrib>Mushtenko, V. V.</creatorcontrib><creatorcontrib>Pushkar, D. Yu</creatorcontrib><creatorcontrib>Matveev, V. B.</creatorcontrib><creatorcontrib>Stilidi, I. S.</creatorcontrib><title>Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer</title><title>Bulletin of experimental biology and medicine</title><addtitle>Bull Exp Biol Med</addtitle><addtitle>Bull Exp Biol Med</addtitle><description>The study compared the levels of MMP-2,7,8,9, and TIMP-1 in blood serum of healthy people (
N
=97) and patients with primary renal cell carcinoma (
N
=93) to assess relevance of these markers to prognosis of overall survival of these patients, which were followed-up over 1 to 45 months (median 26 months). To evaluate the survival with the
Kaplan—Meier
estimator, the median values of examined markers in the total group of patients were taken as the threshold levels. This estimator showed that the high levels of serum MMP-7 and MMP-8 were indicative for
unfavorable prognosis in the total group of patients with r
enal cell cancer. Of them, the most significant marker was the level of MMP-7: at its low level (<6.3 ng/ml), a 3-year survival was 93%, whereas survival dropped down to 51% at a higher value of this marker (
p
<0.001). For MMP-8, the threshold level was 51 ng/ml, and the corresponding survivals were 78 and 58% (
p
<0.01). The level of MMP-7 was also prognostically significant for the patients with stage I kidney cancer: during a 3-year follow-up, all the patients with low MMP-7 were alive, while the 3-year survival of the patients with a high level of MMP-7 was only 72% (
p
=0.02). There were the declining trends for survival at high TIMP-1 and low MMP-2. In contrast, the level of MMP-9 virtually did not correlate with survival of the patients with renal cell cancer.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blood cancer</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Carcinoma, Renal Cell - blood</subject><subject>Carcinoma, Renal Cell - diagnosis</subject><subject>Case-Control Studies</subject><subject>Cell Biology</subject><subject>Comparative analysis</subject><subject>Female</subject><subject>Gelatinase A</subject><subject>Gelatinase B</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - blood</subject><subject>Kidney Neoplasms - diagnosis</subject><subject>Kidneys</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>Matrilysin</subject><subject>Matrix metalloproteinase</subject><subject>Matrix Metalloproteinase 2 - blood</subject><subject>Matrix Metalloproteinase 7 - blood</subject><subject>Matrix Metalloproteinase 8 - blood</subject><subject>Matrix Metalloproteinase 9 - blood</subject><subject>Matrix Metalloproteinases - blood</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Neutrophil collagenase</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Pathology</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Renal cell carcinoma</subject><subject>Tissue inhibitor of metalloproteinase 1</subject><subject>Tissue Inhibitor of Metalloproteinase-1 - blood</subject><subject>Young Adult</subject><issn>0007-4888</issn><issn>1573-8221</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kl1rFDEYhQdRbK3-AS8kIIgXOzVfk2Qu6-JHscWi63XIZN7ZTZlN1iTDur_Av23WrdqKSC5Ckucc3kNOVT0l-JRgLF8lghsia0xxjbmUqt7eq45JI1mtKCX3q2NcqJorpY6qRyld749YkIfVEaOUK87b4-r7VQxLH1J2Fn0KI6AwoEuTo_uGLiGbcQybGDI4bxIkRGdIzpCaoRYZ36PFClxEi90GEEELl9IE6NyvXOdyiMh59HoMoUefIU7rvfGVyQ58Tmjr8gp9cL2HHZobbyE-rh4MZkzw5GY_qb68fbOYv68vPr47n59d1JZLlmtiheAct5YbIfteYNsNvVTGNrJriVAdEWawTHbYENU2CuzQUWqBiUEKbgg7qV4efEusrxOkrNcuWRhH4yFMSVOmBGe0aVRBn_-FXocp-jJdoVoiWyzYLWppRtDODyFHY_em-kxQ1ZSfYqxQp_-gyuph7WzwMLhyf0fw4pZgBWbMqxTGKbvg012QHkAbQ0oRBr2Jbm3iThOs9zXRh5roUhP9syZ6W0TPbqJN3Rr635JfvSgAOwCpPPklxD_Z_2P7A02rxKs</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Kushlinskii, N. E.</creator><creator>Gershtein, E. S.</creator><creator>Alferov, A. A.</creator><creator>Bezhanova, S. D.</creator><creator>Mushtenko, V. V.</creator><creator>Pushkar, D. Yu</creator><creator>Matveev, V. B.</creator><creator>Stilidi, I. S.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200301</creationdate><title>Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer</title><author>Kushlinskii, N. E. ; Gershtein, E. S. ; Alferov, A. A. ; Bezhanova, S. D. ; Mushtenko, V. V. ; Pushkar, D. Yu ; Matveev, V. B. ; Stilidi, I. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-1c664409c4a67dd60cbfd78ac57b9168b16afc37b0a18958ecfb22ce36f764a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blood cancer</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Carcinoma, Renal Cell - blood</topic><topic>Carcinoma, Renal Cell - diagnosis</topic><topic>Case-Control Studies</topic><topic>Cell Biology</topic><topic>Comparative analysis</topic><topic>Female</topic><topic>Gelatinase A</topic><topic>Gelatinase B</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - blood</topic><topic>Kidney Neoplasms - diagnosis</topic><topic>Kidneys</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>Matrilysin</topic><topic>Matrix metalloproteinase</topic><topic>Matrix Metalloproteinase 2 - blood</topic><topic>Matrix Metalloproteinase 7 - blood</topic><topic>Matrix Metalloproteinase 8 - blood</topic><topic>Matrix Metalloproteinase 9 - blood</topic><topic>Matrix Metalloproteinases - blood</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Neutrophil collagenase</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Pathology</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Renal cell carcinoma</topic><topic>Tissue inhibitor of metalloproteinase 1</topic><topic>Tissue Inhibitor of Metalloproteinase-1 - blood</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kushlinskii, N. E.</creatorcontrib><creatorcontrib>Gershtein, E. S.</creatorcontrib><creatorcontrib>Alferov, A. A.</creatorcontrib><creatorcontrib>Bezhanova, S. D.</creatorcontrib><creatorcontrib>Mushtenko, V. V.</creatorcontrib><creatorcontrib>Pushkar, D. Yu</creatorcontrib><creatorcontrib>Matveev, V. B.</creatorcontrib><creatorcontrib>Stilidi, I. S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bulletin of experimental biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kushlinskii, N. E.</au><au>Gershtein, E. S.</au><au>Alferov, A. A.</au><au>Bezhanova, S. D.</au><au>Mushtenko, V. V.</au><au>Pushkar, D. Yu</au><au>Matveev, V. B.</au><au>Stilidi, I. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer</atitle><jtitle>Bulletin of experimental biology and medicine</jtitle><stitle>Bull Exp Biol Med</stitle><addtitle>Bull Exp Biol Med</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>168</volume><issue>5</issue><spage>673</spage><epage>676</epage><pages>673-676</pages><issn>0007-4888</issn><eissn>1573-8221</eissn><abstract>The study compared the levels of MMP-2,7,8,9, and TIMP-1 in blood serum of healthy people (
N
=97) and patients with primary renal cell carcinoma (
N
=93) to assess relevance of these markers to prognosis of overall survival of these patients, which were followed-up over 1 to 45 months (median 26 months). To evaluate the survival with the
Kaplan—Meier
estimator, the median values of examined markers in the total group of patients were taken as the threshold levels. This estimator showed that the high levels of serum MMP-7 and MMP-8 were indicative for
unfavorable prognosis in the total group of patients with r
enal cell cancer. Of them, the most significant marker was the level of MMP-7: at its low level (<6.3 ng/ml), a 3-year survival was 93%, whereas survival dropped down to 51% at a higher value of this marker (
p
<0.001). For MMP-8, the threshold level was 51 ng/ml, and the corresponding survivals were 78 and 58% (
p
<0.01). The level of MMP-7 was also prognostically significant for the patients with stage I kidney cancer: during a 3-year follow-up, all the patients with low MMP-7 were alive, while the 3-year survival of the patients with a high level of MMP-7 was only 72% (
p
=0.02). There were the declining trends for survival at high TIMP-1 and low MMP-2. In contrast, the level of MMP-9 virtually did not correlate with survival of the patients with renal cell cancer.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32248449</pmid><doi>10.1007/s10517-020-04778-w</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-4888 |
| ispartof | Bulletin of experimental biology and medicine, 2020-03, Vol.168 (5), p.673-676 |
| issn | 0007-4888 1573-8221 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2386432558 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Aged Aged, 80 and over Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Blood cancer Cancer Cancer patients Carcinoma, Renal Cell - blood Carcinoma, Renal Cell - diagnosis Case-Control Studies Cell Biology Comparative analysis Female Gelatinase A Gelatinase B Humans Internal Medicine Kidney cancer Kidney Neoplasms - blood Kidney Neoplasms - diagnosis Kidneys Laboratory Medicine Male Matrilysin Matrix metalloproteinase Matrix Metalloproteinase 2 - blood Matrix Metalloproteinase 7 - blood Matrix Metalloproteinase 8 - blood Matrix Metalloproteinase 9 - blood Matrix Metalloproteinases - blood Medical prognosis Middle Aged Neutrophil collagenase Oncology Oncology, Experimental Pathology Predictive Value of Tests Prognosis Renal cell carcinoma Tissue inhibitor of metalloproteinase 1 Tissue Inhibitor of Metalloproteinase-1 - blood Young Adult |
| title | Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A16%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Role%20of%20Matrix%20Metalloproteinases%202,%207,%208,%209%20and%20Their%20Type%201%20Tissue%20Inhibitor%20in%20Blood%20Serum%20of%20Patients%20with%20Kidney%20Cancer&rft.jtitle=Bulletin%20of%20experimental%20biology%20and%20medicine&rft.au=Kushlinskii,%20N.%20E.&rft.date=2020-03-01&rft.volume=168&rft.issue=5&rft.spage=673&rft.epage=676&rft.pages=673-676&rft.issn=0007-4888&rft.eissn=1573-8221&rft_id=info:doi/10.1007/s10517-020-04778-w&rft_dat=%3Cgale_proqu%3EA628510033%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2391790638&rft_id=info:pmid/32248449&rft_galeid=A628510033&rfr_iscdi=true |